Epigenetic silencing of miR-335 induces migration by targeting insulin-like growth factor-1 receptor in multiple myeloma

References

• Herlihy SE, Lin C, Nefedova Y. Bone marrow myeloid cells in regulation of multiple myeloma progression. Cancer Immunol Immun. 2017;66:1007–1014.
   PubMed Web of Science ®Google Scholar
• de la Puente P, Quan N, Hoo RS, et al. Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma. Haematologica. 2016;101:e307–311.
   PubMed Web of Science ®Google Scholar
• Larocca A, Mina R, Gay F, et al. Emerging drugs and combinations to treat multiple myeloma. Oncotarget. 2017;8:60656–60672.
   PubMedGoogle Scholar
• Lv C, Li F, Li X, et al. MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists. Nat Commun. 2017;8:1036.
   PubMed Web of Science ®Google Scholar
• Lulla AR, Slifker MJ, Zhou Y, et al. miR-6883 family miRNAs target CDK4/6 to induce G1 phase cell-cycle arrest in colon cancer cells. Cancer Res. 2017;77:6902–6913.
   PubMed Web of Science ®Google Scholar
• Di Ruocco F, Basso V, Rivoire M, et al. Alu RNA accumulation induces epithelial-to-mesenchymal transition by modulating miR-566 and is associated with cancer progression. Oncogene. 2018;37:627–637.
   PubMed Web of Science ®Google Scholar
• Manier S, Powers JT, Sacco A, et al. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia. 2017;31:853–860.
   PubMed Web of Science ®Google Scholar
• Dabbah M, Attar-Schneider O, Zismanov V, et al. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation. J Leukoc Biol. 2016;100:761–770.
   PubMed Web of Science ®Google Scholar
• Manier S, Liu CJ, Avet-Loiseau H, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017;129:2429–2436.
   PubMed Web of Science ®Google Scholar
• Feng M, Luo X, Gu C, et al. Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells. J Drug Target. 2015;23:59–66.
   PubMed Web of Science ®Google Scholar
• Cao J, Zhang Y, Yang J, et al. NEAT1 regulates pancreatic cancer cell growth, invasion and migration though mircroRNA-335-5p/c-met axis. Am J Cancer Res. 2016;6:2361–2374.
   PubMed Web of Science ®Google Scholar
• Dong Y, Liu Y, Jiang A, et al. MicroRNA-335 suppresses the proliferation, migration, and invasion of breast cancer cells by targeting EphA4. Mol Cell Biochem. 2018;439:95–104.
   PubMed Web of Science ®Google Scholar
• Sandoval-Bórquez A, Polakovicova I, Carrasco-Véliz N, et al. MicroRNA-335-5p is a potential suppressor of metastasis and invasion in gastric cancer. Clin Epigenetics. 2017;9:114.
   PubMed Web of Science ®Google Scholar
• Cui L, Hu Y, Bai B, et al. Serum miR-335 Level is Associated with the Treatment Response to Trans-Arterial Chemoembolization and Prognosis in Patients with Hepatocellular Carcinoma. Cell Physiol Biochem. 2015;37:276–283.
   PubMedGoogle Scholar
• Wang F, Li L, Piontek K, et al. Exosome - miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology. 2018;67:940–954.
   PubMed Web of Science ®Google Scholar
• Abdi J, Rastgoo N, Li L, et al. Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. J Hematol Oncol. 2017;10:169.
   PubMed Web of Science ®Google Scholar
• Fulciniti M, Amodio N, Bandi RL, et al. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016;6:e380.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Chu ZB, Hu Y, et al. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015;75:4384–4397.
   PubMed Web of Science ®Google Scholar
• Zhang JK, Li YS, Zhang CD, et al. Up-regulation of CRKL by microRNA-335 methylation is associated with poor prognosis in gastric cancer. Cancer Cell Int. 2017;17:28.
   PubMed Web of Science ®Google Scholar
• Lin X, Wang Z, Zhang R, et al. High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia. Clin Transl Oncol. 2015;17:358–364.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Cao H, Chen Z, et al. PAX6, a novel target of miR-335, inhibits cell proliferation and invasion in glioma cells. Mol Med Rep. 2014;10:399–404.
   PubMed Web of Science ®Google Scholar
• Ronchetti D, Lionetti M, Mosca L, et al. An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics. 2008;1:37.
   PubMed Web of Science ®Google Scholar
• Quwaider D, Corchete LA, Misiewicz-Krzeminska I, et al. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. J Hematol Oncol. 2017;10:92.
   PubMed Web of Science ®Google Scholar
• Kassambara A, Jourdan M, Bruyer A, et al. Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell. Nucleic Acids Res. 2017;45:5639–5652.
   PubMed Web of Science ®Google Scholar
• Png KJ, Yoshida M, Zhang XH, et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011;25:226–231.
   PubMed Web of Science ®Google Scholar
• Lin X, Wu L, Zhang Z, et al. MiR-335-5p promotes chondrogenesis in mouse mesenchymal stem cells and is regulated through two positive feedback loops. J Bone Miner Res. 2014;29:1575–1585.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tang Y, Zhu X, et al. Overexpression of MiR-335-5p Promotes Bone Formation and Regeneration in Mice. J Bone Miner Res. 2017;32:2466–2475.
   PubMed Web of Science ®Google Scholar
• Amodio N, D’Aquila P, Passarino G, et al. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation. Expert Opin Ther Targets. 2017;21:91–101.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang LQ, Wong KY, et al. Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma. J Clin Pathol. 2015;68:557–561.
   PubMed Web of Science ®Google Scholar
• Amodio N, Bellizzi D, Leotta M, et al. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 2013;12:3650–3662.
   PubMed Web of Science ®Google Scholar
• Alzrigat M, Jernberg-Wiklund H. The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. RNA Dis. 2017;4:pii: e1529.
   Google Scholar
• Alzrigat M, Párraga AA, Agarwal P, et al. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions. Oncotarget. 2017;8:10213–10224.
   PubMed Web of Science ®Google Scholar
• Hentati-Kallel M, Le Jan S, Bernard P, et al. Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines. Int J Oncol. 2017;50:717–726.
   PubMed Web of Science ®Google Scholar
• Amodio N, Stamato MA, Gullà AM, et al. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016;15:1364–1375.
   PubMed Web of Science ®Google Scholar
• Dohi O, Yasui K, Gen Y, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 2013;42:411–418.
   PubMed Web of Science ®Google Scholar
• Luo LJ, Wang DD, Wang J, et al. Diverse roles of miR-335 in development and progression of cancers. Tumour Biol. 2016;37:15399–15410.
   Google Scholar
• Liu J, Bian T, Feng J, et al. miR-335 inhibited cell proliferation of lung cancer cells by target Tra2β. Cancer Sci. 2018;109:289–296.
   PubMedGoogle Scholar
• Kim Y, Kim H, Park D, et al. miR-335 targets SIAH2 and confers sensitivity to anti-cancer drugs by increasing the expression of HDAC3. Mol Cells. 2015;38:562–572.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Berkova Z, Jones RJ, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012;120:3260–3270.
   PubMed Web of Science ®Google Scholar
• Liang SB, Yang XZ, Trieu Y, et al. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134. Clin Cancer Res. 2011;17:4693–4704.
   PubMed Web of Science ®Google Scholar
• Moreau P, Cavallo F, Leleu X, et al. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia. 2011;25:872–874.
   PubMed Web of Science ®Google Scholar